ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: A systematic review of the literature

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Alivernini, Stefano ^a   Laria, Antonella ^a   Gremese, Elisa ^a   Zoli, Angelo ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION;

EID: 77952493476     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2848     Document Type: Article

References (20)

1. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):ii13-16. 1766753, 14532140.
2. Combe B. Switching between anti-TNFalpha agents: what is the evidence?. Joint Bone Spine 2004, 71:169-171. 10.1016/j.jbspin.2003.10.009, 15182784.
3. Levels of Evidence of the Oxford Centre for Evidence-Based Medicine. , http://www.cebm.net/index.aspx?o=1025
4. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356-2359. 15570634.
5. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Emery P, Reece R, Quinn M. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007, 57:448-453. Erratum in: Arthritis Rheum 2007, 57:886, 10.1002/art.22617, 17394231.
6. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007, 66:893-899. 10.1136/ard.2006.068304, 17412737.
7. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, . on behalf of the Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007, 46:1191-1199. 10.1093/rheumatology/kem091, 17504821, on behalf of the Research in Active Rheumatoid Arthritis (ReAct) Study Group.
8. Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006, 65:257-260. 1798023, 15975964, 10.1136/ard.2005.039099.
9. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, . REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627, REFLEX Trial Group.
10. Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, . Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis B cell depletion may be more effective than switching to an alternative anti tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti tumor necrosis factor agents. Arthritis Rheum 2007, 56:1417-1423. 10.1002/art.22520, 17469098, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
11. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123. 10.1056/NEJMoa050524, 16162882.
12. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6 month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714. 2756956, 19074911, 10.1136/ard.2008.099218.
13. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008, 67:1516-1523. 10.1136/ard.2008.092932, 18625622.
14. Pietrapertosa D, Salaffi F, Peluso G, Bosello SL, Fedele AL, Cuoghi I, Michelutti A, Gremese E, Ferraccioli GF. Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. Rheumatology (Oxford) 2009, 48:1242-1246. 10.1093/rheumatology/kep217, 19635732.
15. Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Bambara LM, Triolo G, Ferraccioli G, Valentini G, Lapadula G, . on behalf of GISEA (Gruppo Italiano per lo Studio delle Early Arthritis) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007, 66:249-252. 10.1136/ard.2006.058776, 16837489, on behalf of GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
16. Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, . British Society for Rheumatology Biologics Register Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor agent in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:13-20. 10.1002/art.22331, 17195186, British Society for Rheumatology Biologics Register.
17. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, . GO-AFTER study investigators Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221. 10.1016/S0140-6736(09)60506-7, 19560810, GO-AFTER study investigators.
18. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo R-M. Lack of efficacy of a third tumour necrosis factor a antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006, 45:1121-1124. 10.1093/rheumatology/kel054, 16510526.
19. Smolen JS, Alasti F, Aletaha D. Application of the clinical disease activity index (CDAI) which does not comprise an acute phase reactant (APR) reveals the efficacy of tocilizumab irrespective of the inclusion of an APR for assessment of response. Ann Rheum Dis 2009, 68(Suppl 3):355.
20. Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ, Bresnihan B, FitzGerald O. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1148-1152. 10.1093/rheumatology/kem074, 17478471.